| 1 (56) | Samsung Corp * | MUL |  |
| 2 (81) | AstraZeneca * | MUL | |
| 3 (93) | GlaxoSmithKline * | MUL | |
| 4 (103) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA | |
| 5 (156) | Bayer * | MUL | |
| 6 (166) | GlaxoSmithKline, United Kingdom | GBR | |
| 7 (178) | Bristol-Myers Squibb Company * | MUL | |
| 8 (185) | Sanofi, France | FRA | |
| 9 (187) | Sanofi, United States | USA | |
| 10 (190) | GlaxoSmithKline, United States | USA | |
| 11 (202) | Merck * | MUL | |
| 12 (209) | Bristol-Myers Squibb Company, United States | USA | |
| 13 (213) | Hoffmann-La Roche Ltd, United States | USA | |
| 14 (226) | Genentech Inc | USA | |
| 15 (228) | AstraZeneca, Sweden | SWE | |
| 16 (234) | F Hoffmann-La Roche * | MUL | |
| 17 (239) | AstraZeneca, United Kingdom | GBR | |
| 18 (242) | Regeneron Pharmaceuticals Inc | USA | |
| 19 (243) | Novartis Institutes for Biomedical Research, United States | USA | |
| 20 (244) | Merck & Co Inc, United States | USA | |
| 21 (285) | Boehringer Ingelheim * | MUL | |
| 22 (294) | AstraZeneca, United States | USA | |
| 23 (310) | Novartis * | MUL | |
| 24 (311) | Eli Lilly * | MUL | |
| 25 (316) | Boehringer Ingelheim GmbH Germany | DEU | |
| 26 (336) | Novartis, Switzerland | CHE | |
| 27 (347) | Sanofi * | MUL | |
| 28 (377) | Eli Lilly and Company, United States | USA | |
| 29 (385) | Janssen Biotech Inc | USA | |
| 30 (450) | Janssen | MUL | |
| 31 (466) | Johnson & Johnson * | MUL | |
| 32 (531) | Robert Bosch * | MUL | |
| 33 (551) | Ormat Technologies, United States | USA | |
| 33 (551) | Ormat Technologies Inc * | MUL | |
| 35 (582) | Boehringer Ingelheim, USA | USA | |
| 36 (617) | Bosch, Germany | DEU | |
| 37 (683) | Novartis Pharmaceuticals, United States | USA | |
| 38 (931) | Takeda Pharmaceuticals International Inc * | MUL | |
| 39 (1315) | Manipal Global Education Group * | MUL | |
|
